An Eli Lilly pharmaceutical plant set to manufacture a Covid-19 treatment has been cited by the Food and Drug Administration (FDA) for quality control issues, according to Reuters.
Eli Lilly Plant Set To Manufacture Covid-19 Therapy Cited For Breaching FDA Regulations
